<!-- Intellitrials: Daily Life Sciences M&A Tracker -->
<section class="it-ma">
  <style>
    .it-ma { font-family: system-ui, -apple-system, Segoe UI, Roboto, Arial, sans-serif; }
    .it-ma h2 { margin: 0 0 10px 0; font-size: 20px; }
    .it-ma .meta { margin: 0 0 14px 0; color: #555; font-size: 13px; }
    .it-ma table { width: 100%; border-collapse: collapse; border: 1px solid #e6e6e6; }
    .it-ma th, .it-ma td { padding: 10px 10px; border-bottom: 1px solid #eee; vertical-align: top; }
    .it-ma th { text-align: left; font-size: 13px; letter-spacing: .02em; text-transform: uppercase; background: #fafafa; }
    .it-ma td { font-size: 14px; }
    .it-ma a { text-decoration: none; }
    .it-ma a:hover { text-decoration: underline; }
    .it-ma .tag { display: inline-block; font-size: 12px; padding: 2px 8px; border-radius: 999px; background: #f2f2f2; margin-right: 6px; }
    .it-ma .muted { color: #666; font-size: 13px; }
  </style>
  <h2>M&A Tracker</h2>
  <p class="meta"><strong>Last updated:</strong> 2026-02-15 (America/New_York) • Source links included</p>
  <table>
    <thead>
      <tr>
        <th style="width:110px;">Date</th>
        <th>Acquirer / Buyer</th>
        <th>Target / Asset</th>
        <th style="width:140px;">Deal value</th>
        <th style="width:130px;">Stage</th>
        <th>Notes</th>
        <th style="width:110px;">Source</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td>2026-01-13</td>
        <td><strong>Eli Lilly</strong></td>
        <td><strong>Ventyx Biosciences</strong></td>
        <td>~$1.2 billion</td>
        <td><span class="tag">Announced</span></td>
        <td>Lilly acquires Ventyx and its IL-15 inhibitor for recurrent pericarditis and other cardiovascular/autoimmune conditions.</td>
        <td><a href="https://pharmaphorum.com/news/abivax-climbs-lilly-takeover-speculation" target="_blank" rel="noopener">Link</a></td>
      </tr>
      <tr>
        <td>2026-01-12</td>
        <td><strong>Eli Lilly (rumored)</strong></td>
        <td><strong>Abivax</strong></td>
        <td>€15 billion (~$17.5B)</td>
        <td><span class="tag">Rumored</span></td>
        <td>French reports suggest Lilly is preparing offer for Abivax's obefazimod (ulcerative colitis/IBD). Abivax CEO has dismissed reports as "noise" with no formal discussions confirmed.</td>
        <td><a href="https://www.pharmaceutical-technology.com/news/jpm26-eli-lilly-reportedly-eyes-e15bn-takeover-of-abivax/" target="_blank" rel="noopener">Link</a></td>
      </tr>
      <tr>
        <td>2026-01-08</td>
        <td><strong>Merck (rumored)</strong></td>
        <td><strong>Revolution Medicines</strong></td>
        <td>$28-32 billion</td>
        <td><span class="tag">Rumored</span></td>
        <td>MSD reportedly in talks to acquire Revolution Medicines for its late-stage oral cancer treatment Daraxonrasib. Would be largest biotech deal since Pfizer-Seagen.</td>
        <td><a href="https://sherwood.news/business/big-pharma-enters-2026-with-an-appetite-for-deals/" target="_blank" rel="noopener">Link</a></td>
      </tr>
      <tr>
        <td>2026-01-07</td>
        <td><strong>Merck & Co.</strong></td>
        <td><strong>Cidara Therapeutics</strong></td>
        <td>~$9.2 billion</td>
        <td><span class="tag">Completed</span></td>
        <td>Merck completed acquisition of Cidara for its Phase 3 long-acting flu antiviral CD388 (now MK-1406). Deal closed via tender offer at $221.50/share.</td>
        <td><a href="https://www.merck.com/news/merck-to-complete-acquisition-of-cidara-therapeutics/" target="_blank" rel="noopener">Link</a></td>
      </tr>
      <tr>
        <td>2026-01-05</td>
        <td><strong>PharmaDrug</strong></td>
        <td><strong>Canurta Inc.</strong> (initial 19.9% interest)</td>
        <td class="muted">Not disclosed</td>
        <td><span class="tag">Completed</span></td>
        <td>Initial minority stake acquisition + debt restructuring (per company announcement).</td>
        <td><a href="https://www.biospace.com/press-releases/pharmadrug-completes-acquisition-of-initial-19-9-interest-in-canurta-inc-and-completes-debt-restructuring" target="_blank" rel="noopener">Link</a></td>
      </tr>
      <tr>
        <td>2026-01-05</td>
        <td><strong>W. L. Gore & Associates</strong></td>
        <td><strong>Medtech company</strong> behind foam-based LAAO system</td>
        <td class="muted">Not disclosed</td>
        <td><span class="tag">Announced</span></td>
        <td>Expansion of Gore's medical division via acquisition of an LAAO technology platform (per report).</td>
        <td><a href="https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/w-l-gore-associates-acquire-medtech-company-behind-foam-based-laao-system" target="_blank" rel="noopener">Link</a></td>
      </tr>
      <tr>
        <td>2026-01-05</td>
        <td><strong>Inspira</strong></td>
        <td><strong>Advanced liquid biopsy (cancer)</strong> (term sheet)</td>
        <td class="muted">~$12M earmarked (structure noted)</td>
        <td><span class="tag">Term sheet</span></td>
        <td>Signed a term sheet for acquisition; details include planned allocation of proceeds to fund ongoing ops (per release).</td>
        <td><a href="https://natlawreview.com/press-releases/inspira-signs-term-sheet-acquisition-advanced-liquid-biopsy-cancer" target="_blank" rel="noopener">Link</a></td>
      </tr>
      <tr>
        <td>2025-12-28</td>
        <td><strong>Johnson & Johnson</strong></td>
        <td><strong>Halda Therapeutics</strong></td>
        <td>~$3.05 billion</td>
        <td><span class="tag">Completed</span></td>
        <td>Closed acquisition adding Halda's RIPTAC™ platform and clinical-stage prostate cancer program HLD-0915 (per J&J press release).</td>
        <td><a href="https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies" target="_blank" rel="noopener">Link</a></td>
      </tr>
    </tbody>
  </table>
</section>
